Neoplasms

All Conditions

Nervous System Diseases

Rare Diseases

Glioblastoma

Glioma

Brain Neoplasms

Diffuse Intrinsic Pontine Glioma

Astrocytoma

Oligodendroglioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Brain Stem Neoplasms

Infratentorial Neoplasms

Anaplastic Astrocytoma

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Cetuximab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Participants in this group will receive Cetuximab and Bevacizumab infusion into an artery each month for up to approximately one year.

Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)

SIACI of cetuximab and bevacizumab

Heather McCrea, MD

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients \< 22 years of age.

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

The number of treatment-related adverse events will be assessed and graded according to the NCI Common Toxicity Criteria, version 5.0.

The overall response proportion along with a 95% confidence interval will be estimated via binomial proportions. We will define "evaluable" patients as patients who met eligibility requirements and have initiated therapy.

PFS will be measured from the date of the first dose of SIACI Cetuximab/Avastin to the date of progression.

OS will be measured from the date of diagnosis to the date of death

University of Miami

Assistant Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age	NCT05956821	Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M	SIACI of cetuxi...	1 Year - 21 Years	University of Miami
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age	NCT05956821	Glioblastoma Mu... Anaplastic Astr... Fibrillary Astr... Oligodendroglio... Diffuse Intrins... Diffuse Intrins... DIPG Brain Tumo... H3 K27M	SIACI of cetuxi...	1 Year - 21 Years	University of Miami

Spots Global Cancer Trial Database for siaci of cetuximab and bevacizumab